scholarly journals Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas

2016 ◽  
Vol 51 (5) ◽  
pp. 654-662 ◽  
Author(s):  
F Heinzelmann ◽  
W Bethge ◽  
D W Beelen ◽  
M Engelhard ◽  
N Kröger ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Curative Therapy ◽  
Follicular Lymphomas

scholarly journals Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors

Blood ◽  
2012 ◽  
Vol 120 (7) ◽  
pp. 1367-1379 ◽  
Author(s):  
Vikas Gupta ◽  
Parameswaran Hari ◽  
Ronald Hoffman
Keyword(s):  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Treatment Strategies ◽  
Significant Risk ◽  
Clinical Situation ◽  
Hematopoietic Cell ◽  
Inhibitor Therapy ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Curative Therapy ◽  
Modern Drug

Abstract The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF). Although JAK1/2 inhibitor therapy is effective in decreasing the burden of symptoms associated with splenomegaly and MF-related constitutional symptoms, it is neither curative nor effective in reducing the risk of leukemic transformation. Presently, allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for MF. A significant risk of regimen-related toxicities, graft failure, and GVHD are major barriers to the success of HCT in MF. Because of significant HCT-associated morbidity and mortality, divergent opinions regarding its appropriate role in this clinical situation have emerged. In this review, the risk-benefit ratios of modern drug therapy compared with HCT in MF patients are analyzed. A risk-adapted approach individualized to each patient's biologic characteristics and comorbidities is described, which is currently warranted in determining optimal treatment strategies for patients with MF. Inclusion of JAK1/2 inhibitor therapy in future transplant conditioning regimens may provide an opportunity to overcome some of these barriers, resulting in greater success with HCT for MF patients.

Impact of Palifermin on Transplant Outcomes in Children and Adolescents Undergoing Allogeneic Hematopoietic Cell Transplantation

2020 ◽  
Vol 40 (11) ◽  
pp. 6531-6537
Author(s):  
KRZYSZTOF CZYŻEWSKI ◽  
ROBERT DĘBSKI ◽  
NATALIA BARTOSZEWICZ ◽  
EWA DEMIDOWICZ ◽  
MONIKA RICHERT-PRZYGOŃSKA ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Transplant Outcomes
Sign in / Sign up

Export Citation Format

Share Document